Kayne Anderson Rudnick Investment Management LLC cut its stake in shares of Sanofi (NYSE:SNY) by 0.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,619 shares of the company’s stock after selling 294 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Sanofi were worth $2,473,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. Pennsylvania Trust Co raised its position in shares of Sanofi by 0.4% in the 2nd quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock worth $402,000 after acquiring an additional 37 shares in the last quarter. Rehmann Capital Advisory Group raised its position in shares of Sanofi by 0.7% in the 2nd quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock worth $347,000 after acquiring an additional 47 shares in the last quarter. Weik Investment Services Inc. increased its position in Sanofi by 0.9% during the 1st quarter. Weik Investment Services Inc. now owns 5,895 shares of the company’s stock valued at $267,000 after buying an additional 50 shares in the last quarter. Financial Advisors Network Inc. increased its position in Sanofi by 1.0% during the 1st quarter. Financial Advisors Network Inc. now owns 8,282 shares of the company’s stock valued at $409,000 after buying an additional 84 shares in the last quarter. Finally, First City Capital Management Inc. increased its position in Sanofi by 0.3% during the 1st quarter. First City Capital Management Inc. now owns 38,289 shares of the company’s stock valued at $1,733,000 after buying an additional 100 shares in the last quarter. Institutional investors own 9.33% of the company’s stock.
A number of research analysts recently weighed in on the company. BidaskClub lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Argus lifted their target price on Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Friday, June 2nd. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Finally, Cowen and Company restated a “market perform” rating and issued a $52.00 price target (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. Sanofi has an average rating of “Hold” and an average target price of $54.00.
TRADEMARK VIOLATION WARNING: “Kayne Anderson Rudnick Investment Management LLC Has $2.47 Million Stake in Sanofi (SNY)” was reported by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://baseballnewssource.com/markets/kayne-anderson-rudnick-investment-management-llc-lowers-holdings-in-sanofi-sny/1600299.html.
In related news, major shareholder Sanofi acquired 105,820 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were purchased at an average price of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.00% of the stock is currently owned by insiders.
Shares of Sanofi (NYSE:SNY) opened at 48.76 on Friday. The stock has a 50 day moving average price of $48.29 and a 200 day moving average price of $47.28. Sanofi has a one year low of $36.81 and a one year high of $50.24. The company has a market capitalization of $122.47 billion, a PE ratio of 11.62 and a beta of 0.88.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting analysts’ consensus estimates of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. On average, equities research analysts predict that Sanofi will post $3.34 earnings per share for the current year.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with our FREE daily email newsletter.